Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | SCN1A | P35498 | 5/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.49 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295743 | 0.98 | KDM4E (0.59) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| Hydrochloric Acid SCHEMBL15048692 | 0.98 | KDM4E (0.59) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| SCHEMBL10369755 | 0.93 | CHRM3 (0.55) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| SCHEMBL14624133 | 0.88 | KDM4E (0.56) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| SCHEMBL4208765 | 0.87 | KDM4E (0.55) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| SCHEMBL20561976 | 0.85 | EPHX2 (0.58) | KDM4EMEN1KMT2AMAPTLMNA | |
| SCHEMBL17559489 | 0.85 | IKBKB (0.51) | KDM4ESMN1; SMN2NPY1RNPY2RLMNA | |
| SCHEMBL16295818 | 0.85 | SCN1A (0.60) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| Lithium Ion SCHEMBL16295742 | 0.85 | KDM4E (0.54) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A | |
| SCHEMBL18043814 | 0.85 | EPHX2 (0.47) | KDM4ESMN1; SMN2NPY1RNPY2RSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3008068-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2020-12-30 | — | — | EP | disclosed |
| US-9505769-B2 | Tetraaza-cyclopenta[a]indenyl derivatives | ASCENEURON SA (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2794608-B1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9403835-B2 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2016-05-19 | — | — | US | disclosed |
| EP-3008068-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | Asceneuron SA (CH) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014198808-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | ASCENEURON SA (CH) | 2014-12-18 | — | — | WO | disclosed |
| EP-2794608-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2674434-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137648-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL DERIVATIVES | CHRM1, CHRM2, CHRM3 | KDM4E 3060/4885SMN1; SMN2 3628/4885NPY1R 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.